Biopharma Daily Stock Updates - 01/25/21

$XBI $157.14 (+3.00%) 📈


COVID:

$MRNA (+12.20%) - Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa


$EBS (-0.75%) & HGEN (-2.04%) - Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumabâ„¢


$DVAX (+25.48%) - Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan


PIPELINE:

$AUPH (+26.04%) - Approval


$EIGR (-0.93%) - Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvyâ„¢ (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies


$DRRX (+6.22%) - DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis


$ALBO (+3.76%) - Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat


$ABEO (+9.91%) - Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITALâ„¢ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)


DTIL (+1.28%) - Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma


$AZN (+1.43%) - Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia


$AZN (+1.43%) - Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia


$CYCN (-0.90%) - Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards


FINANCIAL:

$BHVN (+8.52%) - BIOHAVEN ANNOUNCES PRELIMINARY 4Q2020 NET PRODUCT REVENUE FOR NURTEC® ODT


$GNFT (-4.26%) - GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms


$ONCS (-0.69%) - OncoSec Medical Closes $42.0 Million Public Offering of Common Stock

0 comments

*Disclaimer: Information provided on bpiq.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Moversâ„¢ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.

SITE